Drug Libraray

DRACPC ID DRACPC0043

Active Ingredients Rebimastat

Description A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. Rebimastat selectively inhibits several MMPs (MMP 1, 2, 8, 9, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.

Synonyms BMS-275291; D2163; N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide; Rebimastat

Type Small Molecule

Disease Lung cancer, Prostate cancer

Classification

MMP inhibitor Peptide and derivative

Molecular Formula C23H41N5O5S

Molecular Weight 499.7

Active Sequence Not available

Sequence Length Not available

Modification Not available

Structure

Show IUPAC/InChI/SMILES

IUPAC Name (2S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide

InChI InChI=1S/C23H41N5O5S/c1-13(2)12-14(17(29)26-16(19(31)24-8)22(3,4)5)25-18(30)15(34)10-11-28-20(32)23(6,7)27(9)21(28)33/h13-16,34H,10-12H2,1-9H3,(H,24,31)(H,25,30)(H,26,29)/t14-,15-,16+/m0/s1

InChI_Key GTXSRFUZSLTDFX-HRCADAONSA-N

SMILES CC(C[C@@H](C(N[C@H](C(NC)=O)C(C)(C)C)=O)NC([C@H](CCN(C1=O)C(C(C)(N1C)C)=O)S)=O)C

PubChem CID 9913881

DrugBank Accession Number DB06573

NCI Thesaurus Code C1875

UNII 1B47R6ZX4K GSRS

CAS 259188-38-0

Drug indication
Investigated for use/treatment in lung cancer and prostate cancer.

The drug is not approved.

ClinicalTrials.gov Identifier	Title	Condition or disease	Phase	Purpose
NCT00040755	Randomized Phase II Trial of BMS-275291 (NSC 713763, IND 62573) in Hormone Refractory Prostate Cancer	Adenocarcinoma of the Prostate; Bone Metastases; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer	Phase 2	Treatment
NCT00039104	A Phase II, Open-Label, Randomized Trial of Zoledronic Acid (Zometa™) and BMS-275291 (NSC#713763) in Patients With Hormone Refractory Prostate Cancer	Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage IV Prostate Cancer	Phase 2	Treatment
NCT00024024	A Phase I-II Trial Of BMS-275291 In Patients With HIV-Related Kaposi's Sarcoma	Sarcoma	Phase 1/2	Treatment
NCT00006229	A Phase II/III Double Blind Randomized Trial of BMS-275291 vs. Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer	Lung Cancer	Phase 2/3	Treatment

More clinical information is obtained from ClinicalTrials.gov.